Logo

An NCATS Deal

Mar 15, 2012

Eli Lilly has a new partnership with the US National Center for Advancing Translational Sciences, reports the Nature News Blog. Lilly is going to screen more than 3,800 approved and investigational drugs that are part of the center's collection, and the company says it will post its results publicly. "This innovative collaboration with Lilly is exactly the type of partnership that NCATS is eager to foster with many other groups from industry, government and academia," said NCATS Acting Director Thomas Insel in a statement.

Breaking News
The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.